Letter Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Xiangyi Dai, Chonglin Liu, Wei Li, Xiaojun Ma, Kaiping Jiang Tags: Letter to the Editor Source Type: research
Impact of Teratoma on Survival Probabilities of Patients with Metastatic Non-Seminomatous Germ Cell Cancer: Results from the IGCCCG Update Consortium
To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Emanuel B ührer, David D'Haese, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A. Gietema, Ugo De Giorgi, Fay H. Cafferty, Aaron R. Hansen, Torgrim Tandstad, Robert A. Huddart, Andrea Necchi, Christoph Tags: Original Research Source Type: research
Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 28, 2024 Category: Cancer & Oncology Authors: James A. Thomas, Bradley J. Kendall, Graeme A. Macdonald, Aaron P. Thrift Source Type: research
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Theresa Ruf, Rafaela Kramer, Andrea Forschner, Ulrike Leiter, Friedegund Meier, Lydia Reinhardt, Pia D ücker, Carolin Ertl, Dirk Tomsitz, Julia K. Tietze, Ralf Gutzmer, Evelyn Dabrowski, Lisa Zimmer, Anja Gesierich, Sarah Zierold, Lars E. French, Thomas Tags: Original Research Source Type: research
Response to letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Pien Debets, Koen M.A. Dreijerink, Anton Engelsman, Max Dahele, Harm R. Haak, Rebecca V. Steenaard, Ellen Kapiteijn, Eleonora Corssmit, Willemien Menke – van der Houven van Oordt Tags: Letter to the Editor Source Type: research
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Nicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, Anthony Bergeron, Laurent Arnould, Fran çoise Beltjens, Didier Mayeur, Courèche Kaderbhai, Audrey Hennequin, Clémentine Jankowski, Marie Martine Padeano, Hélène Costaz, Sarah Jacinto, Eloise Tags: Original Research Source Type: research
REVOLUMAB: A phase II trial of Nivolumab in recurrent IDH mutant high-grade gliomas.
Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy and safety of the anti-PD1 Nivolumab in patients with recurrent IDHm HGGs. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Picca Alberto, Touat Mehdi, Belin Lisa, Gourmelon Carole, Harlay Vincent, Cuzzubbo Stefania, Cohen-Jonathan Moyal Elizabeth, Bronnimann Charlotte, Di Stefano Anna Luisa, Laurent Isaura, Julie Lerond, Carpentier Catherine, Bielle Franck, Ducray Fran çois, Tags: Clinical Trial Source Type: research
EORTC QLQ-C30 general population normative data for the United States
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 is a frequently used cancer-specific health-related quality of life (HRQoL) questionnaire. To aid interpretation of data obtained via EORTC QLQ-C30, general population norm data have been published for many countries. However, despite its frequent use in the United States, no normative data by sex and age exist to date. Therefore, this study aimed to generate sex- and age-specific EORTC QLQ-C30 normative data for the United States. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Aliz é A. Rogge, Gregor Liegl, Claire Snyder, Matthias Rose, Sandra Nolte, on behalf of the EORTC Quality of Life Group Tags: Original Research Source Type: research
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Mathilde Moreau, Emily Alouani, Cl émence Flecchia, Antoine Falcoz, Claire Gallois, Edouard Auclin, Thierry André, Romain Cohen, Antoine Hollebecque, Anthony Turpin, Simon Pernot, Thérèse Masson, Frederic Di Fiore, Marie Dutherge, Thibault Mazard, Vi Tags: Original Research Source Type: research
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study
We present results of the prespecified interim futility analysis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Atsuo Takashima, Pilar Garc ía-Alfonso, Raimundo Manneh, Ali Ayberk Beşen, Yong Sang Hong, Pieter-Jan Cuyle, Patricio Yanez, Matthew Burge, Takayuki Yoshino, Tae Won Kim, Karen Cui, Chenxiang Li, Rishi Jain, David Adelberg, Julien Taieb Tags: Original Research Source Type: research
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts
In the Netherlands, use of neoadjuvant radiotherapy for rectal cancer declined after guideline revision in 2014. This decline is thought to affect the clinical nature and treatability of locally recurrent rectal cancer (LRRC). Therefore, this study compared two national cross-sectional cohorts before and after the guideline revision with the aim to determine the changes in treatment and survival of LRRC patients over time. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 20, 2024 Category: Cancer & Oncology Authors: E.G.M. van Geffen, J.M.A. Langhout, S.J.A. Hazen, T.C. Sluckin, S. van Dieren, G.L. Beets, R.G.H. Beets-Tan, W.A.A. Borstlap, J.W.A. Burger, K. Horsthuis, M.P.W. Intven, A.G.J. Aalbers, K. Havenga, A.W.K.S. Marinelli, J. Melenhorst, J. Nederend, H.M.U. Pe Tags: Original Research Source Type: research
Ibrutinib plus Venetoclax in the Phase 3 Sympatico Study: what do the censoring rules tell us about the combination therapy?
Progression free survival is a frequently used primary endpoint of randomized clinical trials in cancer. Kaplan Meier method is broadly used to analyze progression free survival data. In Kaplan Meier method only patients with the event of interest contribute to the analysis. Patients that do not contribute to dataset are usually censored. Kaplan-Meier method is based on the assumption that the censored patients are not different than those who contribute to the dataset. Breaking this central assumption can lead to major imbalance in survival analysis. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 20, 2024 Category: Cancer & Oncology Authors: Vadim Lesan, Timoth ée Olivier, Vinay Prasad Tags: Current Perspective Source Type: research
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Rikke B. Holmstroem, Sidsel Pedersen, Rebecca Jurlander, Kasper Madsen, Marco Donia, Christina H. Ruhlmann, Henrik Schmidt, Charlotte A. Haslund, Lars Bastholt, Inge Marie Svane, Eva Ellebaek Tags: Original Research Source Type: research
Paclitaxel Therapeutic Drug Monitoring - International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations
Paclitaxel, one of the most frequently used anticancer drugs, is dosed by body surface area, which leads to substantial inter-individual variability in systemic drug exposure. We evaluated clinical evidence regarding the scientific rationale and clinical benefit of individualized paclitaxel dosing based on measured systemic concentrations, known as therapeutic drug monitoring (TDM). In retrospective studies, higher systemic exposure is associated with greater toxicity and efficacy of paclitaxel treatment across several disease types and dosing regimens. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Daniel L. Hertz, Markus Joerger, Yung-Jue Bang, Ron H. Mathijssen, Caicun Zhou, Li Zhang, David Gandara, Michael Stahl, Bradley J. Monk, Ulrich Jaehde, Jan H. Beumer Tags: Review Source Type: research
Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: a nationwide, population-based cohort study
Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can improve risk prediction remains unclear. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 17, 2024 Category: Cancer & Oncology Authors: Thomas Wagner, Birgitte Gr ønkær Toft, Jakob Lauritsen, Mikkel Bandak, Ib Jarle Christensen, Birte Engvad, Michael Kreiberg, Mads Agerbæk, Lars Dysager, Andreas Carus, Josephine Julie Rosenvilde, Daniel Berney, Gedske Daugaard Tags: Original Research Source Type: research